Evolution Biotechnologies | 2016 July
0
archive,date,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Bedford, UK, and Austin, Texas; July 8th 2016 Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced its sponsorship of the forthcoming EMBO Viruses of Microbes (#EMBOVoM2016) meeting in Liverpool (http://events.embo.org/16-virus-microbe/ ). The company will attend the meeting both to promote its new activities in the area and to recruit staff for its expanded operations. Dr. David Harper, Chief Officer of Evolution, said “I am delighted that the company is supporting this important meeting, and look forward to attending along with other company staff.” About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027 / US...

­Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced an important development in its operations, with the establishment of its therapeutic division. This will work to develop the therapeutic use of bacteria-killing viruses, or bacteriophages, an approach known as phage therapy. This is recognised as a highly promising approach to the control of antibiotic-resistant bacterial infections. Dr. David Harper, the founder and Chief Officer of Evolution has unique experience in this area, having previously run the only modern clinical trial to demonstrate the efficacy of the approach, and demonstrated the effectiveness...